Devyser Diagnostics AB
DVYSR.XSTO
Devyser Diagnostics AB, a prominent biotechnology company, specializes in the development, manufacturing, and distribution of diagnostic test kits built on unique genetic testing technology. The primary function of Devyser Diagnostics AB's products is to provide rapid and reliable diagnostic solutions in areas such as hereditary diseases, oncology, and post-transplantation monitoring. By enabling comprehensive genetic analysis, these kits help healthcare professionals deliver precise disease diagnostics and personalized treatment plans. Devyser’s technology plays a critical role in clinical laboratories worldwide, enhancing the accuracy and efficiency of DNA analysis. The company’s focus on innovation and quality has established it as a key player within the molecular diagnostics industry, gaining a reputation for simplifying complex genetic tests into user-friendly formats. These advancements not only improve patient outcomes but also streamline operations within the healthcare sector, particularly in genomics and precision medicine. Through continuous research and development, Devyser Diagnostics AB remains at the forefront of molecular diagnostics, driving advancements in genetic testing that are essential for modern healthcare frameworks.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 250M
▲ +15.5% YoY
Net Income (TTM)
kr 15M
▲ +86.3% YoY
Op. Margin
9.47%
▲ +33.5pp YoY
ROIC
2.23%
▲ +13.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 24M
▲ +51.4% YoY
Op. Cash Flow (TTM)
kr 46M
▲ +110.7% YoY
Net Debt
-kr 26M
Net Cash Position
Cash & Equiv.
kr 78M
3Y CAGR: +25.5%
Continue Research
Peers
Medical Devices · Pick stocks to compare with DVYSR.XSTO
Devyser Diagnostics AB (DVYSR.XSTO) in four numbers
Questions about Devyser Diagnostics AB
Is Devyser Diagnostics AB (DVYSR.XSTO) overvalued?
At €5.81, Devyser Diagnostics AB's price is 402% above the €1.16 a share fair value that Intrinsiqq's calculator gets from its earnings. It trades at 69.63 times earnings. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Devyser Diagnostics AB's fair value?
Intrinsiqq's calculator puts Devyser Diagnostics AB's fair value at €1.16 a share. It grows earnings per share 5% a year for 5 years, applies an exit P/E of 17.5, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of €0.87. Every input can be changed on the Intrinsic Value tab.
Is Devyser Diagnostics AB a high-quality business?
Devyser Diagnostics AB scores 44 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 7 checks computed from company filings. Its best check is revenue growth at 25.5%, and its weakest is return on capital at 2.2%. The Quality tab shows every check against its target.
Does Devyser Diagnostics AB (DVYSR.XSTO) pay a dividend?
No. Devyser Diagnostics AB (DVYSR.XSTO) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 6 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing DVYSR.XSTO
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.